Skip to main content
. 2022 Aug 9;144(4):747–765. doi: 10.1007/s00401-022-02478-5

Fig. 4.

Fig. 4

Clinical outcomes for patients with NF1-associated gliomas treated with MEK inhibitors. Swimmer’s plot (top) showing treatment course and clinical outcomes for nine NF1-associated glioma patients whose treatment included either trametinib or selumetinib. Imaging (bottom) demonstrating tumor regression for patient #3 and stable disease for patient #34 while on MEK inhibitor therapy